Ignite Creation Date:
2025-12-24 @ 10:18 PM
Ignite Modification Date:
2026-02-02 @ 9:48 PM
Study NCT ID:
NCT05069935
Status:
TERMINATED
Last Update Posted:
2023-09-21
First Post:
2021-09-10
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Sponsor:
Fate Therapeutics
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Solid Tumor, Adult | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | anti-PD-1 / PD-L1 antibodies approved | View |
| None | HER2+ | View |
| None | Metastatic CRC | View |
| None | Head and Neck Squamous Cell Carcinoma | View |
| None | NK Cells | View |
| None | Urothelial Cancer | View |
| None | Renal Cell Carcinoma | View |
| None | merkel cell carcinoma | View |
| None | non-small cell lung cancer | View |
| None | NSCLC | View |
| None | triple negative breast cancer | View |
| None | immune checkpoint inhibitor | View |
| None | melanoma, renal cell carcinoma, lung cancer, | View |
| None | triple-negative breast cancer, | View |
| None | head and neck squamous cell carcinoma, | View |
| None | urothelial carcinoma (UC), | View |
| None | Merkel cell carcinoma, squamous | View |
| None | hepatocellular carcinoma | View |
| None | gastric cancer, esophageal cancer, endometrial cancer, | View |